天津發展(00882.HK)附屬擬1.2億元出售天津田邊製藥24.65%股權
格隆匯6月28日丨天津發展(00882.HK)發佈公吿,就出售天津田邊製藥有限公司24.65%股權事項,於2024年6月28日,力生製藥與最終中標者遠大醫藥(中國)就出售事項訂立產權交易合同,總代價為人民幣1.2億元。於出售事項完成後,集團將不再持有天津田邊任何權益。
天津田邊為一間於中國成立的有限公司,主要從事生產、加工、銷售中西藥、化學藥品、原料藥、試藥、生物製藥及相關服務,以及提供醫藥信息諮詢。
出售事項符合力生製藥的整體戰略規劃。董事會認為,出售事項將提升集團資產的營運效率、優化集團的資源分配及加強集團的現金流。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.